Traders should monitor future quarterly reports for signs of margin improvement and revenue acceleration from expanded manufacturing capacity. The partnership with a global manufacturer like Sanmina reduces execution risk for scaling production, but adoption pace and regulatory milestones (CE Mark) remain key catalysts.
Price Chart
Executive Summary
Microbot Medical announced a Letter of Agreement with Sanmina Corporation to manufacture its LIBERTY Endovascular Robotic System, expanding manufacturing capacity to meet rising demand and support cost reduction. The agreement adds a second manufacturing site and is expected to improve efficiencies and gross margins, but no financial terms were disclosed.
Key Facts
- Entered into Letter of Agreement with Sanmina Corporation for manufacturing of the LIBERTY System
- Sanmina is a leading global integrated manufacturing solutions provider
- Expands manufacturing capacity to meet expected demand from existing and new accounts
- Part of the company's cost reduction strategy, expected to improve operating efficiencies, lower costs, and expand gross margins
- LIBERTY is the only FDA-cleared single-use, remotely operated robotic system for peripheral endovascular procedures
Financial Impact
No financial terms disclosed; expected to improve gross margins and reduce costs over time
Risk Factors
- Adoption of the LIBERTY System may not grow as expected
- Manufacturing scale-up could face delays or quality issues
- Regulatory approvals outside the U.S. (CE Mark) are uncertain
- Forward-looking statements may not materialize
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-031205 |
| Exhibit: ex99-1.htm | 0001493152-26-031205 |
| Document: 0001493152-26-031205-index-headers.html | 0001493152-26-031205 |
| Document: 0001493152-26-031205-index.html | 0001493152-26-031205 |
| Document: 0001493152-26-031205.txt | 0001493152-26-031205 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | $0.9570 | awaiting T+1 | — | $0.9400 (−1.78%) |
Oct 23, 2026 4d ago | 8-K | $0.9739 $0.9417 | ▼ −3.31% | ▼ −4.02% | $0.9400 (−3.48%) |
Oct 20, 2026 7d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9400 (−0.79%) |
Oct 6, 2026 21d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9400 (−12.15%) |
Oct 6, 2026 21d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9400 (−12.15%) |
Sep 28, 2026 29d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9400 (−24.80%) |
Aug 11, 2026 11w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9400 (−44.05%) |
Jul 21, 2026 14w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9400 (−47.78%) |
Jul 7, 2026 16w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9400 (−50.53%) |
Jun 30, 2026 17w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9400 (−51.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers